SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Aytu BioPharma reports FY2026 revenue $57.6M and Q4 $16.1M

FY2026 net revenue fell to $57.6M from $66.4M, while Q4 net revenue rose to $16.1M (+6.4% YoY). Fourth-quarter Adjusted EBITDA was $0.5M; full-year Adjusted EBITDA was a loss.

AYTU

Aytu BioPharma said fiscal 2026 full-year net revenue was $57.6 million, compared with $66.4 million a year earlier. Fourth-quarter net revenue came in at $16.1 million, up 6.4% from the prior year period. The company also reported fourth-quarter Adjusted EBITDA of $0.5 million and a full-year Adjusted EBITDA loss of…

Related stories